BioCryst Pharma (BCRX) Tops Q2 EPS by 14c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.01 +0.91%
Revenue Growth %: +3.9%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: +3.9%
Financial Fact:
Collaborative and other research and development: 4.26M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of $0.15, $0.14 better than the analyst estimate of $0.01. Revenue for the quarter came in at $163.35 million versus the consensus estimate of $149.82 million.
GUIDANCE:
BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $608.4 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barrick Mining said to delay IPO of American gold business to 2027
- MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance
- Barrick Is Said to Weigh Delaying North America Gold IPO to 2027 - Bloomberg
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
